Table 4 Comparison for characteristics and outcomes of high-dose PTCY group and low-dose PTCY group

Age, years

6.12 (SD = 3.66)

5.96 (SD = 2.48)

0.890

sex, n

male

12

11

0.613

female

5

3

Weight, kg

19.7(SD = 9.0)

18.9 (SD = 5.3)

0.759

Primary diagnosis, n

AML

11

8

0.436

ALL

6

5

others

0

1

Remission status, n

CR1

14

13

0.385

CR2

3

1

HLA matching 2, n

7/10 or 8/10

11

6

0.224

9/10 or 10/10

6

8

TNC,10⁷/kg (range)

7.1 (3.39, 13.9)

6.8 (1.0, 15.3)

0.795

CD34⁺, 10⁵/kg (range)

3.4 (1.26, 10.72)

3.6 (2.26, 6.61)

0.767

Median follow-up, months (range)

18.5 (4.4, 30.0)

13.0 (1.8, 18.1)

0.032

PTCY dose

 40 mg/kg, n

7

 29 mg/kg, n

10

 20 mg/kg, n

3

 10 mg/kg, n

11

Neutrophil engraftment, days (range)

18(13, 38)

14 (12,33)

0.251

PLT engraftment, days (range)

32 (12, 61)

31(14, 45)

0.735

Graft failure, n (%)

1 (6)

0 (0)

0.356

PES, n (%)

13 (77)

12 (86)

0.517

Acute GvHD, n (%)

11 (65)

13 (93)

0.062

Grade 3 to 4 Acute GvHD, n (%)

5 (29)

8 (57)

0.119

HC, n (%)

2 (12)

5 (36)

0.134

Chronic GvHD, n (%)

5 (29)

8 (57)

0.119

CMV activity, n (%)

3 (18)

2 (14)

0.597

pneumonia, n (%)

6 (35)

4 (29)

0.497

Fungal infection, n (%)

3 (18)

4 (29)

0.383

Sepsis or bacteremia, n (%)

8 (47)

2 (14)

0.058

TRM, n (%)

2 (12)

1 (7)

0.665

Relapse, n (%)

6 (35)

0 (0)

0.013

Event-free survival, n (%)

9 (53)

13 (93)

0.015

RFS, mean (95%CI)

52.9 (29.18, 76.61)

92.9 (79.38, 100)

0.047

OS, mean (95%CI)

64.7 (41.96, 87.43)

92.9 (79.38, 100)

0.281